# Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast
Canonical URL: https://biopharmsignal.com/news/BRKR/bruker-announces-date-and-time-of-second-quarter-2026-earnings-release-and-webca-29470a21
Ticker: BRKR
Company: Bruker
Source: Bruker
Published: 2026-07-24 20:01 EST
Original Source URL: https://ir.bruker.com/press-releases/press-release-details/2026/Bruker-Announces-Date-and-Time-of-Second-Quarter-2026-Earnings-Release-and-Webcast/default.aspx
## Summary

Bruker Corporation (Nasdaq: BRKR) today announced it will report second quarter 2026 financial results before market opening on Tuesday, August 4, 2026. The Company will host a conference call and webcast at 9:00 a.m. Eastern Daylight Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q2 2026 Earnings Webcast” hyperlink in the “Events Presentations” section. A slide presentation will be referenced during the webcast and will be posted to the Company’s website shortly before the webcast begins. Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-412-317-6702 (international) and referencing “Bruker’s Second Quarter 2026 Earnings Conference Call.” Bruker is enabling investors to pre-register for the earnings conference call so that they can expedite their entry into the call and avoid the need to wait for a live operator. In order

## Article Body
Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast

Bruker Corporation (Nasdaq: BRKR) today announced it will report second quarter 2026 financial results before market opening on Tuesday, August 4, 2026. The Company will host a conference call and webcast at 9:00 a.m. Eastern Daylight Time to discuss the results and current business trends.

To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q2 2026 Earnings Webcast” hyperlink in the “Events & Presentations” section. A slide presentation will be referenced during the webcast and will be posted to the Company’s website shortly before the webcast begins.

Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-412-317-6702 (international) and referencing “Bruker’s Second Quarter 2026 Earnings Conference Call.”

Bruker is enabling investors to pre-register for the earnings conference call so that they can expedite their entry into the call and avoid the need to wait for a live operator. In order to pre-register for the call, investors can visit https://dpregister.com/sreg/10210859/10488dbff5c and enter their contact information. Investors will then be issued a personalized phone number and PIN to dial into the live conference call. Individuals can pre-register any time prior to the start of the conference call on August 4.

A telephone replay of the conference call will be available by dialing 1-855-669-9658 (U.S. toll free) or +1-412-317-0088 (international) and entering replay access code: 2701950. The replay will be available beginning one hour after the end of the conference call through September 4, 2026.

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com .

Joe Kostka

Director, Investor Relations

Bruker Corporation

T: +1 (978) 313-5800

E: [email protected]

Source: Bruker Corporation
## Recent Company News
- 2026-07-24 20:01 EST — [Bruker Announces Date and Time of Second Quarter 2026 Earnings Release and Webcast](https://biopharmsignal.com/news/BRKR/bruker-announces-date-and-time-of-second-quarter-2026-earnings-release-and-webca-29470a21) — Source: Bruker
- 2026-07-15 11:00 EST — [Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER® Platform for Pathogenic Microorganisms in Blood](https://biopharmsignal.com/news/BRKR/bruker-expands-infection-detection-portfolio-with-acquisition-of-metagenomic-mng-36c3ebd1) — Source: Bruker
- 2026-06-04 11:00 EST — [Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026](https://biopharmsignal.com/news/BRKR/bruker-showcases-expanding-microbiology-and-infection-diagnostics-portfolio-at-asm-microbe-2026) — Source: Bruker
- 2026-06-02 15:24 EST — [Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry](https://biopharmsignal.com/news/BRKR/bruker-launches-new-timsmrms-mass-spectrometry-platform-for-unique-ultra-complex-mixture-applications-in-the-energy-industry) — Source: Bruker
- 2026-06-01 11:00 EST — [Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology](https://biopharmsignal.com/news/BRKR/bruker-announces-major-strides-in-4d-proteomics-performance-further-advances-in-intact-and-top-down-functional-proteoform-analysis-and-innovations-in-hybrid-qual-quant-4d-metabolomics-all-to-enable-deeper-insights-into-disease-biology) — Source: Bruker
## Related News
- 2026-07-24 19:54 EST — MARKET — [Opinion: I led the FDA’s food safety and nutrition center. Here’s what people are missing about the cyclospora outbreak](https://biopharmsignal.com/news/MARKET/opinion-i-led-the-fda-s-food-safety-and-nutrition-center-here-s-what-people-are--ec3f5220)
- 2026-07-24 18:41 EST — MARKET — [FDA advisory panel narrowly rejects compounding of one peptide, back another](https://biopharmsignal.com/news/MARKET/fda-advisory-panel-narrowly-rejects-compounding-of-one-peptide-back-another-3cd43ff8)
- 2026-07-24 16:13 EST — MARKET — [There are already more U.S. measles cases this year than in all of 2025](https://biopharmsignal.com/news/MARKET/there-are-already-more-u-s-measles-cases-this-year-than-in-all-of-2025-ff246e52)
- 2026-07-24 15:57 EST — MARKET — [STAT+: Up and down the ladder: The latest comings and goings](https://biopharmsignal.com/news/MARKET/stat-up-and-down-the-ladder-the-latest-comings-and-goings-d8f5feca)
- 2026-07-24 13:41 EST — MARKET — [STAT+: Fatal gene-editing trial in China raises ethics and oversight questions](https://biopharmsignal.com/news/MARKET/stat-fatal-gene-editing-trial-in-china-raises-ethics-and-oversight-questions-bf72167a)